Sunshine Biopharma (Sunshine Biopharma) Accounts Receivable : $2.83 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sunshine Biopharma's accounts receivables for the quarter that ended in Mar. 2024 was $2.83 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Sunshine Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 34.22.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sunshine Biopharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $16.40.

Sunshine Biopharma Accounts Receivable Historical Data

The historical data trend for Sunshine Biopharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Accounts Receivable Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.01

1.91

2.55

Sunshine Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															1.79	2.01	2.03	2.55	2.83

Sunshine Biopharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Sunshine Biopharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Sunshine Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.828	/	7.541	*	91
=	34.22

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sunshine Biopharma's accounts receivable are only considered to be worth 75% of book value:

Sunshine Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(17.434	+	0.75 * 2.828	+	0.5 * 7.698	-	7.079
-	0.013	-	0)	/	0.99453
=	16.40

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Sunshine Biopharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Executives

Camille Sebaaly	director, officer: CFO and Secretary	14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun	10 percent owner	1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller	director	10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey	director	6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish	director	6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah	director	924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp	10 percent owner	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty	director, 10 percent owner, officer: CEO and President	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki	director, officer: Chief Operating Officer	731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di	director, officer: Chief Operating Officer	3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3